Salute e Benessere
Non-muscle Invasive Bladder Cancer Market to Reach US$ 21.1 Billion by 2034 with a Projected 21% CAGR | Exclusive Report by Transparency Market Research Inc.
Non-muscle invasive bladder cancer (NMIBC) is referred to as cancer located in tissue lining the bladder's inner surface. The bladder muscle is not playing role over there. Bladder cancer is more prevalent in men as compared to women. It is also common with aging. It is generally seen in age group of 75-84.
Bladder is where body stores urine prior to leaving it. It is a hollow organ in pelvis with muscular, flexible walls. It can get smaller or bigger as per quantity of urine. Urine reaches the bladder through ureters. They push urine through a tube called urethra. Growing incidence of non-muscle invasive bladder cancer worldwide is thus driving the non-muscle invasive bladder cancer market.
Bladder cancer is amongst the top 10 most prevalent cancers worldwide. Moreover, it has been reported that majority of newly diagnosed bladder cancer cases are non-muscle invasive bladder cancers (NMIBC). They are characterized by the cancer cells getting confined to the bladder's inner lining. The governments across the globe are extensively spending on intravesical anti-cancer therapies such as BCG (live attenuated bacteria meant for stimulating an immune response against the cancer cells) or chemotherapy.
Researchers are also investing in maintenance therapy, so that risk of recurrence can be reduced. Regular cystoscopies are also prescribed in order to monitor regarding recurrence. Additional treatments are initiated on detection of new tumors. Increase in healthcare spending by governments as mentioned above is thus expanding the non-muscle invasive bladder cancer market size.
Key participants in the invasive bladder cancer landscape are engaging in inorganic modes of expansion to strengthen their position. For instance, In June 2022 , Cipla inked a distribution agreement with Roche Products ( India ) Pvt. Ltd. in order to expand scope of partnership of including marketing as well as distribution of the latter's branded oncology drugs.
, a global registered at Wilmington, Delaware , United States , provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
:
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
+1-518-618-1030
: 866-552-3453
https://www.transparencymarketresearch.com
sales@transparencymarketresearch.com
LinkedIn Twitter Blog YouTube
Logo - https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/non-muscle-invasive-bladder-cancer-market-to-reach-us-21-1-billion-by-2034-with-a-projected-21-cagr--exclusive-report-by-transparency-market-research-inc-302208702.html